A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase

<div><p>The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising candidates for clinically useful antiviral agents. Studies using these compounds have highlighted the role of IN in both early and late stages of virus replication. However, dissecting the exact mechanism of action of the quinoline-based ALLINIs has been complicated by the multifunctional nature of these inhibitors because they both inhibit IN binding with its cofactor LEDGF/p75 and promote aberrant IN multimerization with similar potencies <i>in vitro</i>. Here we report design of small molecules that allowed us to probe the role of HIV-1 IN multimerization independently from IN-LEDGF/p75 interactions in infected cells. We altered the rigid quinoline moiety in ALLINIs and designed pyridine-based molecules with a rotatable single bond to allow these compounds to bridge between interacting IN subunits optimally and promote oligomerization. The most potent pyridine-based inhibitor, KF116, potently (EC₅₀ of 0.024 µM) blocked HIV-1 replication by inducing aberrant IN multimerization in virus particles, whereas it was not effective when added to target cells. Furthermore, KF116 inhibited the HIV-1 IN variant with the A128T substitution, which confers resistance to the majority of quinoline-based ALLINIs. A genome-wide HIV-1 integration site analysis demonstrated that addition of KF116 to target or producer cells did not affect LEDGF/p75-dependent HIV-1 integration in host chromosomes, indicating that this compound is not detectably inhibiting IN-LEDGF/p75 binding. These findings delineate the significance of correctly ordered IN structure for HIV-1 particle morphogenesis and demonstrate feasibility of exploiting IN multimerization as a therapeutic target. Furthermore, pyridine-based compounds present a novel class of multimerization selective IN inhibitors as investigational probes for HIV-1 molecular biology.</p></div

Genotype of HIV-1 variants selected in cell culture in the presence of KF116.

<p>(<b>A</b>) Mutations in the HIV-1_NL4-3 IN gene of resistant viruses selected with KF116. Clonal sequencing of viral passage was carried out at passages 5 and 10, respectively. Eighty-two clones from each viral passage were sequenced using three sequencing primers covering the entire IN gene. Percentage of IN mutations for a given passage are indicated. Passage 5 corresponds to 50 days of selection with the KF116 concentration reaching 0.8 µM. Passage 10 corresponds to 100 days of selection with the KF116 concentration reaching 25.6 µM. (<b>B</b>) Crystal structure of KF116 bound to HIV-1 IN CCD dimer indicating the Thr-124, Val-165 and Thr-174 residues. The IN subunit 1 and 2 are colored in cyan and green, respectively. KF116 is shown in magenta.</p

Activities of HIV-1 IN inhibitors.

<p>Data for IC₅₀ and EC₅₀ are given as the mean ± SD from at least three independent experiments.</p><p>CC₅₀ values of >100 µM indicates that the respective inhibitors were not cytotoxic at the tested concentrations upto 100 µM.</p>a<p>BI-1001 EC₅₀ value and the assay method have been described elsewhere <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1004171#ppat.1004171-Kessl3" target="_blank">[33]</a>.</p

Crystal structures of LEDGF/IBD (A), BI-1001 (B), KF115 (C), and KF116 (D) bound to HIV-1 IN CCD.

<p>The IN subunit 1 and 2 are colored in cyan and green, respectively. LEDGF/IBD loop (amino acids 365–368) is shown in dark blue. BI-1001 is shown in orange. KF115 is shown in red. KF116 is shown in magenta. The hydrogen bonds between the IN subunit and the LEDGF/IBD or the indicated inhibitors are shown by black dashed lines. Side chains of HIV-1 IN residues A128T and T125 in subunit 1, and E170, H171 and T174 in subunit 2 are shown.</p

Chemical structures of ALLINIs and MINIs.

<p>Chemical structures of ALLINIs and MINIs.</p

Virions produced in the presence of KF116 are defective in reverse transcription.

<p>(<b>A–E</b>) VSV-G pseudotyped HIV-1-Luc produced in the presence of DMSO, 1 µM KF116, or 1 µM RAL were used to infect HEK293T cells. Infected cells were harvested at the indicated times and subjected to quantitative PCR (qPCR) or luciferase assay. Graphs indicate the amount of PCR products relative to non-treated (DMSO) sample at 6 h post-infection for (<b>A</b>) early reverse transcription (Early RT), (<b>B</b>) late reverse transcription (Late RT) and (<b>C</b>) 2-LTR circles (2-LTRs) products. (<b>D</b>) Bar graphs indicate the integrated provirus relative to non-treated (DMSO) control at 7 days post-infection. (<b>E</b>) Aliquots of infected cells were harvested and luciferase assay was performed at 48 h post-infection. The luciferase signal obtained for the non-treated (DMSO) sample was set to 100%. All graphs represent mean ± SD (<i>n</i> = 3). (<b>F–J</b>) HEK293T cells were treated with DMSO, 1 µM KF116, or 1 µM RAL and then infected with VSV-G pseudotyped HIV-1-Luc. Infected cells were harvested at the indicated times and subjected to qPCR or luciferase assay. Graphs indicate the amount of PCR products relative to non-treated (DMSO) sample at 6 h post-infection for (<b>F</b>) early reverse transcription (Early RT), (<b>G</b>) late reverse transcription (Late RT) and (<b>H</b>) 2-LTR circles (2-LTRs) products. (<b>I</b>) Bar graphs indicate the integrated provirus relative to non-treated (DMSO) sample at 7 days post-infection. (<b>J</b>) Aliquots of infected cells were harvested and luciferase assay was performed at 48 h post-infection. The luciferase signal obtained for the non-treated (DMSO) sample was set to 100%. All graphs represent mean ± SD (<i>n</i> = 3).</p

LEDGF/p75 expression does not affect KF116 potency during late stage of HIV-1 replication.

<p>(<b>A</b>) Equivalent whole cell lysates from the clonal TALEN-derived <i>PSIP</i>1 KO cell line (indicated as “KO”) and parental wild type HEK293T cell line (indicated as “WT”) were subjected to SDS-PAGE and immunoblotted for LEDGF/p75 and a GAPDH control to verify knockdown of LEDGF/p75 protein. (<b>B</b>) Dose-response curves representing the antiviral assays performed in WT or KO cell lines under the indicated conditions of drug treatment. For producer cell treatment, the VSV-G pseudotyped HIV-1-Luc progeny virions were prepared in the indicated cell line in the presence of KF116 and were then used to infect untreated HEK293T cells. For target cell treatment, KF116 was added directly to the indicated cell line and the cells were infected with untreated VSV-G pseudotyped HIV-1-Luc virions. (<b>C</b>) EC₅₀ values for the indicated antiviral assays. Results represent mean ± SD from three independent experiments.</p

KF116 selectively impairs the late stage of HIV-1 replication.

<p>(<b>A</b>) Dose-response curves for KF116 antiviral activities during early stage, late stage or one full replication cycle. For early stage experiments, KF116 was added directly to the target cells and then these cells were infected with untreated virions. For late stage experiments, the progeny virions were prepared in the presence of KF116 and were then used to infect untreated target cells. For one full replication cycle experiments, KF116 was added to both producer and target cells. (<b>B</b>) EC₅₀ values for the indicated antiviral assays. Results represent mean ± SD from three independent experiments.</p

Bioactive Flavaglines and Other Constituents Isolated from <i>Aglaia perviridis</i>

Eight new compounds, including two cyclopenta­[<i>b</i>]­benzopyran derivatives (<b>1</b>, <b>2</b>), two cyclopenta­[<i>b</i>]­benzofuran derivatives (<b>3</b>, <b>4</b>), three cycloartane triterpenoids (<b>5</b>–<b>7</b>), and an apocarotenoid (<b>8</b>), together with 16 known compounds, were isolated from the chloroform-soluble partitions of separate methanol extracts of a combination of the fruits, leaves, and twigs and of the roots of <i>Aglaia perviridis</i> collected in Vietnam. Isolation work was monitored using human colon cancer cells (HT-29) and facilitated with an LC/MS dereplication procedure. The structures of the new compounds (<b>1</b>–<b>8</b>) were determined on the basis of spectroscopic data interpretation. The Mosher ester method was employed to determine the absolute configurations of <b>5</b>–<b>7</b>, and the absolute configuration of the 9,10-diol unit of compound <b>8</b> was established by a dimolybdenum tetraacetate [Mo₂(AcO)₄] induced circular dichroism procedure. Seven known rocaglate derivatives (<b>9</b>–<b>15</b>) exhibited significant cytotoxicity against the HT-29 cell line, with rocaglaol (<b>9</b>) being the most potent (ED₅₀ 0.0007 μM). The new compounds <b>2</b>–<b>4</b> were also active against this cell line, with ED₅₀ values ranging from 0.46 to 4.7 μM. The cytotoxic compounds were evaluated against a normal colon cell line, CCD-112CoN. In addition, the new compound perviridicin B (<b>2</b>), three known rocaglate derivatives (<b>9</b>,<b> 11</b>, <b>12</b>), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (<b>17</b>), showed significant NF-κB (p65) inhibitory activity in an ELISA assay

KF116 promotes IN multimerization <i>in vitro</i> and in HIV-1 particles.

<p>(<b>A</b>) DLS analysis of KF116-induced multimerization of recombinant IN. Size distribution of IN at 2 minutes (blue), 8 minutes (red), 30 minutes (green) and 120 minutes (yellow) after addition of KF116. No detectable signal was recorded in control experiments with KF116 alone or IN+DMSO incubated for up to 120 minutes. (<b>B</b>) The schematic to show the inhibitor induced equilibrium shift toward aberrant IN oligomerization. (<b>C</b>) HIV-1 virions were produced in HEK293T cells in the presence of DMSO or 1 µM KF116, cell-free virions were harvested, detergent-lysed, and treated with BS³ cross-linking reagent. The indicated volumes of cross-linked reaction products were resolved by SDS-PAGE and immunoblotted with HIV-1 IN antibody. The bands corresponding to IN “monomer”, “dimer”, and “higher order oligomers” are indicated.</p